EDX MEDICAL & THERMO FISHER SCIENTIFIC TO COLLABORATE ON DEVELOPMENT OF INNOVATIVE CANCER TESTS FOR GLOBAL MARKETS
Cambridge, UK: EDX Medical Group plc (“EDX Medical”), a developer of digital diagnostic products and services for personalised treatment cancer, heart disease and infectious diseases, today announced a collaborative product development agreement with Thermo Fisher Scientific EMEA Ltd. (“Thermo Fisher”), a world leader in supplying life sciences solutions and services.
The collaboration agreement will enable EDX Medical and Thermo Fisher to jointly develop and potentially commercialise a number of clinical-grade assays - including novel and innovative cancer diagnostic solutions. The multi project collaboration will harness Thermo Fisher’s powerful technologies and information translation systems to deliver a number of advanced testing solutions in development at EDX or licensed from partners, including a proprietary assay to enable personalised radiotherapy and a novel chemotherapy toxicity assay focusing on serious adverse events.
The collaboration will leverage combined capabilities to deliver testing solutions being developed at EDX laboratories in Cambridge and Oxford UK, and Ireland.
Professor Sir Chris Evans, founder of EDX Medical, said: “We are delighted to be working closely with such a world leader as Thermo Fisher in order to accelerate the development of our range of exciting new products. These tests will make a real difference to cancer patients. Thermo Fisher’s advanced technologies and knowledge are renowned and coupled with our own scientific team’s focus and expertise, this partnership marks an important milestone in the growth of EDX Medical.”
Dr Mike Hudson, CEO of EDX Medical, said: “This collaboration with Thermo Fisher confirms our capability and ambition to build a significant clinical digital diagnostics business with global scale and impact, cementing both technical and commercial aspects of our laboratory assay business. Our product development pipeline will be enhanced by Thermo Fisher’s knowledge and scalable, class-leading technologies, providing both partners with a means to accelerate the availability of innovative new tests for healthcare professionals and patients around the world.”
Peter Jacobs, Director, EMEA Clinical Business Development, Thermo Fisher Scientific, said: “We are excited at the prospect of working with EDX Medical on a number of their new clinical diagnostic products and are confident that together we will be able to achieve rapid progress and deliver innovative new assays for the global clinical marketplace.”
